TCP-1是一种新型的定向于肿瘤血管的多肽，通过小鼠体内的噬菌体展示技术筛选得到。在之前的研究中，我们已证明TCP-1具有定向于肿瘤血管并有效靶向运输抗肿瘤药物和显像剂的特性。本研究的目的是进一步研究在原位结肠癌模型中定向运输抗肿瘤药物肿瘤坏死因子(TNFα)，以及在结肠癌临床样本中运输显像剂异硫氰酸荧光素(FITC)的能力。并对TCP-1与肿瘤坏死因子的融合蛋白TCP-1/TNFα的抗肿瘤机制进行阐述。 / 本研究中，我们首先尝试用TCP-1作为载体，将增强绿色荧光蛋白靶向运输至肿瘤血管。结果证明TCP-1可以成功将蛋白运输到在肿瘤血管而非其它正常的组织器官上。TCP-1还可以靶向运输肿瘤坏死因子并增强其抗肿瘤作用。和肿瘤坏死因子比较，融合蛋白TCP-1/TNFα处理组的凋亡细胞数量增多，肿瘤微血管数目减少，并且无明显毒副作用。与结肠癌的一线化疗药物5-氟尿嘧啶(5-FU)联合给药后，与TNFα与5-FU联合给药相比较，融合蛋白TCP-1/TNFα联合5-FU在以下方面具有更明显的作用：抑制肿瘤生长，增加肿瘤细胞凋亡和抑制肿瘤细胞增殖，促进肿瘤血管正常化，升高瘤内免疫细胞以及减轻骨髓和脾内的免疫抑制反应。经检测TCP-1的靶向运输增加了瘤内的TNFα以及5-FU的浓度。这些都表明TCP-1不但可以靶向运输TCP-1/TNFα至肿瘤血管，还可以增加CD8+细胞的浸润增加瘤内免疫反应以及增加血管对抗肿瘤药物的通透性。以上都对抗肿瘤起到重要作用。 / 在临床的结肠癌样本中，TCP-1对肿瘤血管的结合能力也得到了证实。48.98%的结肠癌样本对TCP-1的结合为阳性。统计学分析显示TCP-1的结合与结肠癌的分期和肿瘤位置有关，对于N2期，位于乙状结肠的肿瘤的结合尤为明显。本研究的主要目的是将分离鉴定出的TCP-1发展成为结肠癌的生物标记，并且作为运输抗肿瘤药物和显像剂的载体应用于结肠癌的诊断和治疗中。鉴于TCP-1的靶向运输特点，将会有机会研发更多的抗肿瘤药物，同时增强传统化疗药的抗肿瘤作用。这些都可以优化肿瘤治疗的方案。综上所述，TCP-1是一种在结肠癌治疗诊断中具有广阔前景的多肽。 / TCP-1 is a novel vasculature-targeting peptide. It was discovered through the in vivo phage library selection in mice. It was demonstrated that TCP-1 peptide exhibited a homing ability to the neovasculature of colon tumors and was capable of efficiently delivering imaging agents and chemotherapeutic drugs to this target site. The current study is to further investigate the targeting ability of TCP-1 to deliver a known immunomodulator, tumor necrosis factor α (TNFα) as an example of anti-cancer drug in an orthotopic colorectal cancer (CRC) model and fluorescein isothiocyanate (FITC) as imaging agent for testing the binding capacity for tumors in colorectal cancer patients. The mechanisms for the action of this novel biologic TCP-1/TNFα in the treatment of colon cancer in mice were also defined. / In this study, we observed that TCP-1 peptide delivered enhanced green fluorescent protein (EGFP) only to tumor blood vessel other than normal organs after TCP- 1/EGFP injection. This was not observed after EGFP injection. This finding showed that TCP-1 can deliver biologic protein to the tumor blood vessels. Furthermore, results from TNFα or TCP-1/TNFα targeted delivery experiments showed that TCP- 1/TNFα displayed stronger anti-cancer effects than TNFα alone on the induction of apoptosis and reduction in number of microvessels in the tumors, without significant effect in systemic toxicity. In the combined therapy with 5-fluorouracil (5-FU), a standard drug for colon cancer treatment, pretreatment with low dose (1 ng TNFα /mouse) of TNFα or TCP-1/TNFα potentiated the anti-cancer action of 5-FU. In this regard, TCP-1/TNFα could significantly reduce tumor size and weight, increase number of apoptotic cells, inhibit tumor cell proliferation, normalize tumor blood vessels, facilitate infiltration of immune cells to tumor mass and attenuate immunosuppression in bone marrow and spleen. Moreover, TCP-1 could significantly increase intratumoral levels of TNFα and 5-FU. It was also suggested that TCP-1 could selectively deliver TNFα to the tumor blood vessels and modulate the immune response by increasing CD8+ cells infiltration to tumors and increase vascular permeability to 5-FU. These observations may be the key actions to reduce tumor growth. / The binding ability of TCP-1 was also detected in clinical samples from colorectal cancer patients in which 24/49 (48.98%) tumor tissues were positive with TCP-1 binding signal. Statistical analysis showed that TCP-1 had a strong and significant binding with colorectal cancer at the N2 stage among the different colorectal cancer stages (P=0.028) and location in the colon at the sigmoid (P<0.001). / Our study also focused on the isolation and identification of the binding molecule of TCP-1 in order to develop it into a biomarker for CRC and using TCP-1 as a carrier in delivering anti-cancer drugs and imaging agents to colon tumors for cancer therapy and diagnosis. With the homing property of TCP-1 on colon tumor blood vessels, new types of anti-cancer drugs will be developed and their combinations with conventional chemotherapy drugs will optimize the therapeutic outcome and improve regimen of treatment for CRC. Taken together, TCP-1 peptide appears to be a promising agent in molecular imaging and drug delivery for CRC diagnosis and therapy. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Lu, Lan. / Thesis (Ph.D.) Chinese University of Hong Kong, 2014. / Includes bibliographical references (leaves 157-177). / Abstracts also in Chinese. / Lu, Lan.

A tolerância operacional (TO) é um raro fenômeno que ocorre em indivíduos transplantados, que permanecem com função estável do aloenxerto, sem rejeição, após a suspensão de drogas imunossupressoras, por pelo menos um ano. A compreensão de mecanismos envolvidos na tolerância operacional poderá contribuir para a elaboração de novas terapias imunorreguladoras, na clínica do transplante. Investigamos se, no estado de tolerância operacional, há um perfil funcional diferencial de resposta imune celular antígeno-específica, dirigida a três grupos de antígenos relevantes no alotransplante: aloantígenos do doador (peptídeos HLA-DR), antígenos de patógenos (peptídeos do CMV - citomegalovírus) e autoantígenos (peptídeos da Hsp60 - Proteína de choque térmico 60, com funções imunológicas, imunorreguladora (REGULA) e pró-inflamatória (INFLAMA). Analisamos a produção de citocinas (por Luminex) e a proliferação de diferentes subpopulações de células T CD4+ (por FACS), com funções, predominantemente, REGULA ou INFLAMA, frente aos três tipos de antígenos, comparativamente entre TO (n=6) e Rejeição Crônica (RC: n=8), indivíduos com função estável do enxerto, usando imunossupressores (EST: n=8) e indivíduos saudáveis (SAU: n=7). Em concordância com nossa hipótese, a resposta celular é modulada, de forma diferencial, na tolerância operacional, ocorrendo um desvio funcional da resposta a peptídeos HLA-DR do doador para um perfil REGULA, enquanto é preservado o perfil INFLAMA na resposta a peptídeos do patógeno (CMV). Apesar das diferenças nas respostas aos peptídeos do CMV entre TO e RC (p=0,02 e p=0,02 para citocinas e subpopulações regula e p=0,008 e p=0,003 para citocinas e subpopulações inflama), houve preservação do perfil INFLAMA na TO, em relação ao estado fisiológico, com indução/aumento das citocinas inflamatórias IL-1B, IL-17, IFNy, MCP-1 e MIP-1B, com algum grau de inibição de citocinas imunorreguladoras, e inibição da proliferação de células Tregs, sugerindo serem importantes mecanismos na preservação da imunocompetência, na tolerância operacional. Na resposta celular a autoantígenos, destacamos o peptídeo N6 que induziu um perfil significativamente diferente na TO (mais REGULA), em relação à RC (mais INFLAMA) (p=0,001 para citocinas regula; p=0,04 para citocinas inflama), principalmente pelo aumento/indução da produção de IL-4, IL-5, IL-10 e IL-13, na TO, sugerindo que o peptídeo N6 possa ter uma contribuição nos mecanismos na TO, favorecendo a produção dessas citocinas com atividade imunorreguladora. Considerando a diferença significativa do perfil funcional de resposta aos aloantígenos do doador entre TO (REGULA) e RC (INFLAMA) (p=0,0007 para citocinas regula e p < 0,0001 para citocinas inflama), principalmente pela inibição das citocinas próinflamatórias, como IL-1B, IL-8, IL-12, IL-17, G-CSF, IFN-y e MCP-1, na TO, concluímos que o desvio REGULA da via indireta de alorreconhecimento dirigida a peptídeos HLA-DR do doador, com inibição dessas citocinas, tenha um papel importante nos mecanismos envolvidos na tolerância operacional. Em conclusão os mecanismos em curso na tolerância operacional, modulam a resposta celular antígeno-específica dirigida a desafios antigênicos no transplante, envolvendo o desvio REGULA da resposta a peptídeos HLA-DR do doador, a participação da autoimunidade imunorreguladora à Hsp60, ao mesmo tempo em que há preservação da resposta inflamatória a patógenos / Operational tolerance (OT) is a rare phenomenon, taking place in transplanted individual who do not reject, following the complete withdrawal of immunosuppressive drugs for at least one year. Understanding the mechanisms involved in operational tolerance will contribute to opening new pathways for the development of novel immunoregulatory therapies, in transplantation. We investigated whether the state of operational tolerance displays a functionally differential profile of the antigen-specific cellular response, directed to three groups of antigens, relevant in the context of allotransplantation: donor alloantigens (HLA-DR peptides), pathogen-derived antigens (cytomegalovirus peptides - CMV) and autoantigens (peptides derived from the Hsp60 - selfantigen displaying immunoregularory (REG) and proinflammatory (INFLAMMA) properties). We determined cytokine production (by Luminex) and the proliferative response of different CD4+ T cell subsets (by FACS), displaying predominantly REG or INFLAMMA activities, in response to the three types of antigens, comparing OT (n=6) with Chronic Rejection (CR: n=8), individual with stable graft function, taking conventional immunosuppression (Sta: n=8), and healthy individuals (HI: n=7). In concordance with our hypothesis, the cellular immune response is differentially modulated in operational tolerance, giving rise to an immunoregulatory deviation in the response to HLA-DR donor peptides, preserving the proinflammatory response to pathogen peptides (CMV). Despite significant differences in the responses to CMV peptides, between OT and CR (p=0.02 and p=0.02 for REG cytokines and CD4+ subsets; p=0.008 and p=0.003 for INFLAMMA cytokines and CD4+ subsets), OT is able to preserve the INFLAMMA response in relation to the physiologic state (HI). This INFLAMMA profile of the response to CMV peptides is maintained by the induction/increase of the proinflammatory cytokines, IL-1B, IL-17, IFN-y, MCP-1 and MIP-1B, some inhibition of REG cytokines and inhibition of Treg proliferation, suggesting that these are important mechanisms in the preservation of immunocompetence to deal with pathogens, in OT. In the cellular response to autoantigens, we highlight the N6 peptide that induced a differential profile in OT (REG profile) compared to CR (INFLAMMA profile) (p=0.001 for REG cytokines; p=0.04 for INFLAMMA cytokines), due to the induction/increase of IL-4, IL-5, IL-10 e IL-13, in OT, suggesting that N6 may contribute to the underlying mechanisms in OT, favoring the production of these immunoregulatory cytokines. Taken the marked differences in the response to donor alloantigens, between OT (predominantly REG) and CR (predominantly INFLAMMA) (p=0.0007 for REG cytokines and p < 0.0001 for INFLAMMA cytokines), due to the inhibition of the proinflammatory cytokines, IL-1B, IL-8, IL- 12, IL-17, G-CSF, IFN-y and MCP-1, in OT, we conclude that the immunoregulatory deviation in the indirect pathway of allorecognition, directed to donor HLA-DR peptides, leading to the inhibition of these cytokines, has an important role in the mechanisms of tolerance. In conclusion, the ongoing immunoregulatory mechanisms in operational tolerance, modulate the antigenspecific cellular response to relevant antigenic challenges in allotransplantation, involving a REG deviation in the response to donor HLA-DR peptides, together with the participation of immunoregulatory autoimmunity to Hsp60, while preserving the proinflmammatory response to pathogens

A paracoccidioidomicose (PCM) é uma doença sistêmica de caráter granulomatoso, causada pelo fungo termodimórfico Paracoccidioides spp. A PCM é endêmica na America Latina e aproximadamente 80% do pacientes vivem no território brasileiro. O tratamento medicamentoso é eficiente, entretanto, é longo e vários pacientes acabam abandonando e recidivas são comuns neste grupo. A utilização de uma vacina terapêutica poderia resultar na redução do tempo de tratamento assim como, recuperar a resposta imune do hospedeiro frente ao fungo. As vacinas de DNA são uma abordagem promissora na imunoterapia e podem ser injetadas por via intramuscular, intradérmica ou via mucosa. As proteínas de choque térmico (HSPs) são proteínas que estão ligadas a homeostase celular e também possuem efeitos imunológicos em diversos casos como doenças infecciosas e autoimunes. No presente trabalho, analisamos o esquema vacinal terapêutico em camundongos BALB/c previamente infectados intratraquealmente com 3x105 leveduras de P. brasiliensis Pb18, 60 dias depois, submetidos a imunização com pcDNA3 contendo sequências codificadoras de PbHSP60 e/ou IL-12 murina e/ou vetor vazio. Foi observada redução significativa no número de unidades formadoras de colônia (UFCs) nos pulmões de camundongos imunizados com PbHSP60. Os grupos que receberam PbHSP60+pcDNA3 vazio ou PbHSP60x2 apresentaram os maiores índices de redução da cargas fúngicas. A inclusão do plasmídeo contendo o inserto de mIL-12, resultou em um efeito deletério. A análise dos cortes histológicos indicou que os animais vacinados apresentavam áreas bem preservadas e com poucos ou nenhum foco de granuloma. Detectamos um perfil de citocinas típico Th1/Th2. Nossos resultados sugerem que a imunização utilizando plasmídeo contendo o inserto HSP60, tem grande potencial vacinal / The paracoccidioidomycosis (PCM) is a systemic granulomatous disease of character, caused by the thermally dimorphic fungus Paracoccidioides spp. The PCM is endemic in Latin America and approximately 80% of patients are living in Brazil. The medical treatment is effective, however, is long and many patients end up abandoning and relapses are common in this group.The use of a therapeutic vaccine could result in the reducing time of treatment as well as recover the host immune response against the fungus. DNA vaccines are a promising approach for immunotherapy and can be injected by intramuscular, intradermal, or mucosal route. The heat shock proteins (HSPs) are proteins that are linked to cellular homeostasis and also have immunological effects in many cases as infectious and autoimmune diseases. In the present study, we analyzed the therapeutic vaccine schedule in BALB/c mice previously infected intratracheally with 3x105 yeast of P. brasiliensis strain 18, and 60 days after, undergoing immunization with pcDNA3 containing coding sequences PbHSP60 and / or murine IL-12 and / or empty vector. Significant reduction was observed in the number of colony forming units (CFU) in the lungs of mice immunized with PbHSP60. The groups that received empty pcDNA3 and PbHSP60 or PbHSP60x2 have higher rates of reduced fungal loads. The inclusion of the plasmid containing the insert mIL-12 resulted in a deleterious effect. The analysis of histological sections indicated that vaccinated animals had wellpreserved, with few or no focus of granuloma areas. It was detected a profile typical Th1/Th2 cytokines. Our results suggest that immunization using plasmid containing the insert HSP60 vaccine has great potential

In order for G protein signaling to occur, the G protein heterotrimer must be assembled from its nascent polypeptides. The most difficult step in this process is the formation of the Gβγ dimer from the free subunits since both are unstable in the absence of the other. Recent studies have shown that phosducin-like protein (PhLP1) works as a co-chaperone with the cytosolic chaperonin complex (CCT) to fold Gβ and mediate its interaction with Gγ. However, these studies did not address questions concerning the scope of PhLP1 and CCT-mediated Gβγ assembly, which are important questions given that there are four Gβs that form various dimers with 12 Gγs and a 5th Gβ that dimerizes with the four regulator of G protein signaling (RGS) proteins of the R7 family. The data presented in Chapter 2 shows that PhLP1 plays a vital role in the assembly of Gγ2 with all four Gβ1-4 subunits and in the assembly of Gβ2 with all twelve Gγ subunits, without affecting the specificity of the Gβγ interactions. The results of Chapter 3 show that Gβ5-RGS7 assembly is dependent on CCT and PhLP1, but the apparent mechanism is different from that of Gβγ. PhLP1 seems to stabilize the interaction of Gβ5 with CCT until Gβ5 is folded, after which it is released to allow Gβ5 to interact with RGS7. These findings point to a general role for PhLP1 in the assembly of all Gβγ combinations, and suggest a CCT-dependent mechanism for Gβ5-RGS7 assembly that utilizes the co-chaperone activity of PhLP1 in a unique way. Chapter 4 discusses PhLP2, a recently discovered essential protein, and member of the Pdc family that does not play a role in G protein signaling. Several studies have indicated that PhLP2 acts as a co-chaperone with CCT in the folding of actin, tubulin, and several cell cycle and pro-apoptotic proteins. In a proteomics screen for PhLP2A interacting partners, α-tubulin, 14-3-3, elongation factor 1α, and ribosomal protein L3 were found. Further proteomics studies indicated that PhLP2A is a phosphoprotein that is phosphorylated by CK2 at threonines 47 and 52.